Active ingredientElexacaftorCat. No. P-E021-001CAS 2216712-66-0Family · Pharmaceutical analytical standards
Elexacaftor
A CFTR protein corrector used in cystic fibrosis in a triple combination with tezacaftor and ivacaftor. It was approved in the United States in October 2019 for patients aged 12 and over with at least one copy of the F508del mutation. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?A single copy of the F508del mutation is enough to use it: with its arrival it was estimated that about 90% of people with cystic fibrosis could receive an effective targeted therapy.
Go to the active ingredient →Active ingredientElexacaftorCat. No. P-E021-001CAS 2216712-66-0
MetaboliteElexacaftor Metabolite 1Cat. No. P-E021-002CAS 2229860-93-7
Isotopically labelledElexacaftor-13C-d3Cat. No. P-E021-003
NitrosamineN-Nitroso ElexacaftorCat. No. P-E021-004
ImpurityElexacaftor Impurity 1Cat. No. P-E021-005
ImpurityElexacaftor Impurity 2Cat. No. P-E021-006CAS 2229861-17-8
ImpurityElexacaftor Impurity 3Cat. No. P-E021-007No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.